Abstract: The present invention relates to molecules preferably of polypeptide nature with negative regulatory activity on the amount or activity of TGF-? through direct interaction with pro-TGF-?, and containing as active region a cysteine-rich polypeptide sequence defined as “EMI domain”, or its subfragments, wherein said “EMI domain” has at least 25% sequence homology to the ID NO2 sequence for pharmaceutical use. Even more preferably said polypeptide sequence consists of the EMI domain of the following proteins: emilin-1, emilin-2 and/or multimerin-2 or their subfragments having a length of at least 6 amino acids, capable of inhibiting the conversion of pro-TGF? to mature TGF? as anti-hypertensive drugs and polypeptides active on the cardiovascular system.